February 21, 2025

FDA Approves First Cerebrotendinous Xanthomatosis Treatment

The FDA has approved Ctexli (chenodiol) as the first treatment for cerebrotendinous xanthomatosis, a rare lipid storage disorder.

Conexiant

February 20, 2025

Hospital Occupancy to Reach 85% by 2035

The projection is driven by a decline in staffed beds and an aging population.

Conexiant

February 19, 2025

Hospital Occupancy to Reach 85% by 2035

The projection is driven by a decline in staffed beds and an aging population.

Conexiant

February 18, 2025

CDC Reports Increase in Child and Severe Adult Obesity

From 2013 to 2023, severe obesity increased annually by 0.23 percentage points, according to new NHANES data.

Conexiant

February 14, 2025

First Rapid-Acting Insulin Biosimilar Gets FDA Approval

FDA approves Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog for glycemic control in adult and pediatric diabetes patients, expanding treatment accessibility.

Conexiant

February 12, 2025

FDA & EMA: Submitted Trial Data Discrepancies

Sample size discrepancies were identified in 13 trials (65%), with 8 differing by more than 10%.

Conexiant

February 10, 2025

Children With Autism and Medical Complexity Account for Disproportionate Health Care Costs

Children with both autism spectrum disorder and medical complexity have higher health care expenditures than those with autism spectrum disorder or medical complexity alone.

Conexiant

February 10, 2025

Dupilumab for Pediatric EoE: Phase III Histologic Remission Findings

Researchers found that dupilumab improved histologic remission in pediatric patients with eosinophilic esophagitis.

Conexiant

February 10, 2025

Guideline-Based Mental Health Treatment Gaps Identified

Researchers found significant gaps in mental health and substance use disorder treatment.

Conexiant